"Ex vivo" surgery works for abdominal tumors

Share this article:

A novel surgical technique that involves the temporary removal of entire abdominal organs enables surgeons to take out tumors that are unresectable by the usual surgical methods.

In their case report, published in American Journal of Transplantation (2012;12[5]:1323-1328), a team of surgeons led by Tomoaki Kato, MD, of Columbia University, New York, New York, described their removal of tumors in three patients. The tumors involved both the celiac artery and the superior mesenteric artery.

In this new approach, known as multivisceral ex vivo surgery, the entire abdominal viscera were removed, the tumor was cut out, and the blood vessels were reconstructed using synthetic vascular grafts. The organs were then reimplanted into the abdomen, with surgeons reconnecting blood vessels and GI tracts.

All three patients remain alive with no tumor recurrence at 17, 27, and 38 months after surgery. Postoperative complications included diarrhea, sphincter of Oddi dysfunction, and arterial stenosis, all of which responded to directed treatments.

The authors conclude that multivisceral ex vivo surgery may prove to be a useful treatment for tumors thought of as inoperable. They contend that the surgery is most suitable for locally invasive tumors that are unresectable due to location and vascular involvement.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.